Europe
Extracellular vesicles, in short EVs, take part in many vital physiological processes and the progression of diseases, such as cancer, but isolation of EVs remains the bottleneck for their effective utilisation.
Company recently received FDA approval for clinical trial; next generation device, SonoCloud-9, will soon be trialed in US
MorphoSys announced the opening of its new U.S. headoffice. Based in Boston, MA, one of the world’s leading innovation and biotech hubs, the new location will enable MorphoSys to establish and expand its U.S.
The US-based charity Alzheimer’s Association announces a $7 million dollar grant to allow UCL researchers to carry out detailed assessments of individuals from the 1946 birth cohort.
Financial returns from US to be shared with the UK NHS via Sensyne’s unique partnership model
Motif Bio plc of the Company held earlier in New York, all resolutions put to shareholders were duly passed.
It was a busy week for clinical trial announcements. Here’s a look.
Under the terms of the agreement, Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion based on the achievement of certain predetermined development, regulatory and commercial milestones.
People deserve a personalized approach in cancer treatment that considers their unique genetic traits and the latest medical research — this methodology stands a significantly increased chance of pushing back against the disease.
The research pact will leverage Dewpoint’s biomolecular condensates technology platform and Bayer’s small molecule compound library to identify and develop new therapies for cardiovascular and gynecological diseases.
PRESS RELEASES